Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 104 participants.

Also called NCT02946632

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 104 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02946632
Other papers using this trial's data
  • Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add-on therapy in drug-naïve patients with type 2 diabetes (TRIPLE-AXEL study): A multicentre, randomized, 104-week, open-label, active-controlled trial Diabetes, obesity & metabolism, 2024-09 DOI, PubMed 38853720

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02946632. Randomized; no masking; primary purpose treatment. Start 2016-12 (registry gives no type); primary completion 2019-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes
Condition
Diabetes Mellitus, Type II
Intervention (Drug)
triple combination therapy
Intervention (Drug)
Stepwise add-on therapy
Lead sponsor
Korea University Anam Hospital (class: other)
Collaborator
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02946632
Content hash
c5eb566dbc3ae3e2ce6202ce2704e2fe908ea958abc817ffffaa30a57d01ed5e